SOUTH SAN FRANCISCO, Calif.--(

加利福尼亚州南旧金山--(

BUSINESS WIRE

商业热线

)--

)--

Veracyte, Inc.

Veracyte公司。

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.

领先的癌症诊断公司（纳斯达克：VCYT）今天宣布，2025年ASCO泌尿生殖系统癌症研讨会（ASCO GU）上提供的新数据证明了其Decipher前列腺和Decipher膀胱测试的性能和临床实用性，以帮助指导前列腺癌和膀胱癌患者的治疗。

Presented findings also show that the company’s Decipher GRID (Genomic Resource for Intelligent Discovery) research tool is enabling new data-based insights that in the future may help further advance personalized cancer care. The findings are from among 17 Decipher-focused abstracts being presented at the conference this week in San Francisco, as well as a new paper published in .

研究结果还表明，该公司的Decipher GRID（智能发现基因组资源）研究工具正在实现新的基于数据的见解，未来可能有助于进一步推进个性化癌症护理。这些发现来自于本周在旧金山举行的会议上提交的17篇以破译为重点的摘要，以及发表在上的一篇新论文。

Annals of Oncology.

肿瘤学年鉴。

“The breadth and depth of Decipher-focused data presented at the ASCO GU Symposium reinforce the widespread impact our Decipher tests are having on clinical care, as well as on research into the molecular underpinnings of prostate and bladder cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.

Veracyte泌尿科医学主任Elai Davidioni博士说：“ASCO GU研讨会上提供的以解密为重点的数据的广度和深度加强了我们的解密测试对临床护理以及前列腺癌和膀胱癌分子基础研究的广泛影响。”。

“They also demonstrate Veracyte’s commitment to clinical rigor and evidence development. We are grateful for our ongoing collaborations with leading clinician-researchers, which are enabling us to continue driving innovation that can further help patients.”.

“他们还证明了Veracyte对临床严谨性和证据开发的承诺。我们感谢我们与领先的临床医生研究人员的持续合作，这使我们能够继续推动创新，进一步帮助患者。”。

Key findings presented at the ASCO GU Symposium are:

Poster (Abstract #399): Decipher Score as a Predictor of Response to Treatment Intensification in the NRG Oncology-RTOG 0534 (SPPORT) Phase III Randomized Post-Prostatectomy Salvage Radiotherapy Trial. Presented by Alan Pollack, M.D., Ph.D., University of Miami Health System.

海报（摘要#399）：Decipher评分作为NRG肿瘤学RTOG 0534（SPPORT）III期随机前列腺切除术后挽救放疗试验中治疗强化反应的预测指标。由迈阿密大学卫生系统医学博士Alan Pollack介绍。

This study found that the Decipher Prostate Genomic Classifier may inform treatment-intensification strategies for patients undergoing salvage radiotherapy by identifying those who will benefit from pelvic nodal radiation. The findings are from a post-hoc analysis of the NRG Oncology/RTOG 0534 (SPPORT) Phase 3, randomized trial.

这项研究发现，Decipher前列腺基因组分类器可以通过识别那些将从盆腔淋巴结放疗中受益的患者，为接受挽救性放疗的患者提供治疗强化策略。这些发现来自NRG肿瘤学/RTOG 0534（SPPORT）第3阶段随机试验的事后分析。

Decipher Prostate test results were obtained for 709 patients who experienced biochemical recurrence following prostatectomy and were allocated to three treatment study arms: 1.) prostate bed radiation therapy alone (PBRT); 2.) PBRT and short-term androgen deprivation therapy (STADT); or 3.) PBRT, STADT and pelvic lymph node radiation therapy (PLNRT).

对709例前列腺切除术后生化复发的患者进行了Decipher前列腺测试，并将其分为三个治疗研究组：1）单独前列腺床放射治疗（PBRT）；2）PBRT和短期雄激素剥夺疗法（STADT）；或3。）PBRT，STADT和盆腔淋巴结放射治疗（PLNRT）。

They found that patients with high Decipher Prostate scores received greater benefit from the addition of PLNRT and STADT to PBRT, compared to those with low genomic test scores..

他们发现，与基因组测试分数低的患者相比，解密前列腺分数高的患者从PBRT中添加PLNRT和STADT获得了更大的益处。。

“The addition of pelvic node radiotherapy to PBRT and short-term ADT is becoming more frequently used for patients with high-risk prostate cancer undergoing salvage radiation,” said Dr. Davicioni, an author on the study. “Accurately determining which patients are likely to benefit from this strategy, however, can be challenging but is especially important given its additional toxicity and potential side effects.

该研究的作者Davidioni博士说：“对于接受挽救性放疗的高危前列腺癌患者，在PBRT和短期ADT中增加盆腔淋巴结放疗的频率越来越高。”。“然而，准确确定哪些患者可能从这种策略中受益可能具有挑战性，但鉴于其额外的毒性和潜在的副作用，这一点尤为重要。

Our findings show that Decipher Prostate test results can provide physicians with important information to help guide treatment decision-making with their patients.”.

我们的研究结果表明，解密前列腺测试结果可以为医生提供重要信息，帮助指导患者的治疗决策。”。

Poster (Abstract #831): A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. Presented by Yair Lotan, M.D., UT Southwestern Medical Center.

海报（摘要#831）：一种基于非编码RNA的分类器，可在临床器官局限性膀胱癌中获得良好的预后。由犹他州西南医学中心医学博士Yair Lotan介绍。

In this study, researchers demonstrated that the Decipher Bladder Genomic Subtyping Classifier accurately identified patients whose bladder cancer was less aggressive, based on their cancer’s molecular subtype. The study involved 226 patients with high-grade, clinically organ-confined bladder cancer who subsequently underwent radical cystectomy without any neoadjuvant therapy.

在这项研究中，研究人员证明，Decipher膀胱基因组亚型分类器可以根据癌症的分子亚型准确识别膀胱癌侵袭性较低的患者。这项研究涉及226名患有高度，临床器官局限性膀胱癌的患者，他们随后接受了根治性膀胱切除术，没有任何新辅助治疗。

The researchers found that patients with the luminal favorable bladder cancer subtype, compared to those without it, had significantly lower likelihood of being upstaged to T3+ disease (OR 0.32, 95% CI 0.12-0.82; P= 0.02) or to any upstaging (OR 0.41, 95% CI 0.20-0.83; P=0.01). They also found that the luminal favorable subtype was significantly associated with better overall survival (HR 0.33, 95% CI 0.15-0.74; P=0.007)..

研究人员发现，与没有管腔有利膀胱癌亚型的患者相比，具有管腔有利膀胱癌亚型的患者发生T3+疾病（OR 0.32，95%CI 0.12-0.82；P=0.02）或任何升级（OR 0.41，95%CI 0.20-0.83；P=0.01）的可能性显着降低。他们还发现，管腔有利的亚型与更好的总生存率显着相关（HR 0.33，95%CI 0.15-0.74；P=0.007）。。

“Accurate clinical staging in bladder cancer can be challenging, limiting clinicians’ ability to guide treatment decisions for their patients,” said Dr. Lotan. “Our findings suggest that molecular subtyping information provided by the Decipher Bladder test can help physicians better identify which patients have less-aggressive bladder cancer and may not require treatment intensification.”.

洛坦博士说：“准确的膀胱癌临床分期可能具有挑战性，限制了临床医生指导患者治疗决策的能力。”。“我们的研究结果表明，Decipher膀胱测试提供的分子亚型信息可以帮助医生更好地确定哪些患者的膀胱癌侵袭性较低，可能不需要强化治疗。”。

Oral Presentation (Abstract #308): Gene signature predictor of dose-response to prostate radiation: validation of PORTOS in phase III trials. Presented by Shuang Zhao, M.D., University of Wisconsin-Madison.

口头介绍（摘要#308）：前列腺辐射剂量反应的基因特征预测因子：III期试验中PORTOS的验证。由威斯康星大学麦迪逊分校医学博士赵爽介绍。

This study’s oral presentation at the ASCO GU Symposium also corresponded with its publication in

这项研究在ASCO GU研讨会上的口头报告也与其在

Annals of Oncology

肿瘤学年鉴

. The findings demonstrate that PORTOS (Post-Operative Radiation Therapy Outcomes Score), a genomic signature developed using Veracyte’s Decipher GRID research tool, predicts which patients with prostate cancer are likely to benefit from differing dosages of salvage and definitive radiation therapy.

研究结果表明，使用Veracyte的Decipher GRID研究工具开发的基因组特征PORTOS（术后放射治疗结果评分）可以预测哪些前列腺癌患者可能会从不同剂量的挽救和确定性放射治疗中受益。

The findings are from post-hoc analyses of the SAKK 09/10 and NRG Oncology/RTOG 0126 Phase 3, randomized clinical trials..

这些发现来自SAKK 09/10和NRG肿瘤学/RTOG 0126第3阶段随机临床试验的事后分析。。

Among the 226 patients evaluated from the SAKK 09/10 trial, those with higher PORTOS scores were significantly more likely to benefit from dose-increased (70 Gy vs. 64 Gy) salvage radiotherapy, compared to those with lower PORTOS scores. Additionally, among 215 patients undergoing definitive radiotherapy in the NRG Oncology/RTOG 0126 trial, those with higher PORTOS scores were more likely to benefit from dose escalation (79.2 Gy vs.

在SAKK 09/10试验评估的226例患者中，与PORTOS评分较低的患者相比，PORTOS评分较高的患者更有可能受益于剂量增加（70 Gy vs.64 Gy）的挽救性放疗。此外，在NRG肿瘤学/RTOG 0126试验中接受明确放疗的215例患者中，PORTOS评分较高的患者更有可能从剂量递增中受益（79.2 Gy vs。

70.2 Gy), compared to those with lower PORTOS scores. An analysis using the whole-transcriptome-based Decipher GRID research tool’s database showed that there were no strong associations between the PORTOS signature and clinicopathologic variables such as race, PSA levels, clinical stage, grade group or NCCN risk status..

70.2 Gy），与PORTOS得分较低的人相比。使用基于全转录组的Decipher GRID研究工具的数据库进行的分析表明，PORTOS特征与临床病理变量（例如种族，PSA水平，临床分期，年级组或NCCN风险状态）之间没有很强的关联。。

“Physicians are currently limited in their tools for determining which patients with prostate cancer will benefit from dose-escalated radiation therapy. Our findings, derived from two Phase 3, randomized trials, suggest that the research-based PORTOS signature has potential to be a useful clinical tool to help inform important radiation treatment decisions for patients following a prostate cancer diagnosis or who are experiencing biochemical recurrence,” said Dr.

“医生目前在确定哪些前列腺癌患者将从剂量递增放射治疗中受益方面的工具有限。我们的研究结果来自两项3期随机试验，表明基于研究的PORTOS特征有可能成为一种有用的临床工具，有助于为前列腺癌诊断后或生化复发患者的重要放射治疗决策提供信息，”Dr。

Zhao, who also helped develop the PORTOS signature..

赵，他也帮助开发了波尔图的签名。。

About Decipher Prostate

关于解密前列腺

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment.

解密前列腺基因组分类器是一种22基因测试，使用RNA全转录组分析和机器学习开发，有助于为前列腺癌患者的治疗决策提供信息。该测试是在活检或手术切除的样本上进行的，并通过标准治疗提供了发生转移的准确风险。

Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients.

有了这些信息，医生可以更好地个性化患者的护理，并可能为风险较低的患者推荐较不密集的选择，或为转移风险较高的患者推荐更早，更密集的治疗。Decipher前列腺测试已经在涉及10多万名患者的数十项已发表研究中得到验证。

It is the only gene expression test to achieve “Level IB” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found .

这是唯一达到“IB级”证据状态并纳入最新NCCN®前列腺癌指南*风险分层表的基因表达测试。有关解密前列腺测试的更多信息可以找到。

here

在这里

.

.

About Decipher Bladder

关于解密膀胱

The Decipher Bladder Genomic Subtyping Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications.

Decipher膀胱基因组亚型分类器是一种219基因测试，使用RNA全转录组分析和机器学习开发，旨在用于膀胱癌诊断后面临治疗强度问题的患者。该测试将膀胱肿瘤分为五种分子亚型，每种亚型都具有不同的肿瘤生物学和潜在的临床意义。

This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found .

这些信息可以帮助医生和他们的患者更好地了解新辅助化疗可能获得的益处程度和/或手术时携带非器官局限性疾病的可能性。可以找到有关解密膀胱测试的更多信息。

here

在这里

.

.

About Decipher GRID

关于解密网格

The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis.

Decipher GRID数据库包括来自泌尿系统癌症患者的超过200000个全转录组谱，Veracyte及其合作伙伴使用该数据库为继续研究做出贡献，并帮助增进对前列腺癌和其他泌尿系统癌症的了解。网格衍生信息仅在研究使用的基础上可用。

More information about Decipher GRID can be found .

。

here

在这里

.

.

About Veracyte

关于Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development.

Veracyte（纳斯达克股票代码：VCYT）是一家全球诊断公司，其愿景是为全世界的患者转变癌症护理。我们为临床医生提供所需的高价值见解，以指导和确保患者在诊断和治疗癌症的关键时刻。我们的Veracyte诊断平台提供了高性能的癌症测试，这些测试由广泛的基因组和临床数据，深入的生物信息学和人工智能能力以及强大的证据生成引擎提供支持，最终推动了我们测试的持久报销和指南纳入，以及支持持续创新和管道开发的新见解。

For more information, please visit .

有关更多信息，请访问。

www.veracyte.com

www.veracyte.com

and follow the company on LinkedIn and X (formerly Twitter) at @veracyte.

并在@veracyte的LinkedIn和X（前推特）上关注该公司。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的注意事项

This press release contains forward-looking statements, including, but not limited to our statements related to the potential for Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer and Decipher GRID to enable new data-based insights that may in the future help further advance personalized cancer care; that the Decipher Prostate Genomic Classifier may inform treatment-intensification strategies for patients undergoing salvage radiotherapy by identifying those who will benefit from pelvic nodal radiation; that the findings suggest that the Decipher Bladder test can help physicians better identify which patients have less-aggressive bladder cancer and may not require treatment intensification; and that the PORTOS signature has potential to be a useful clinical tool to help inform important radiation treatment decisions for patients following a prostate cancer diagnosis or who are experiencing biochemical recurrence.

本新闻稿包含前瞻性声明，包括但不限于我们关于解密前列腺和解密膀胱测试潜力的声明，以帮助指导前列腺癌和膀胱癌患者的治疗，以及解密网格，以实现新的基于数据的见解，可能在未来有助于进一步推进个性化癌症护理；Decipher前列腺基因组分类器可以通过识别那些将从盆腔淋巴结放疗中受益的患者，为接受挽救性放疗的患者提供治疗强化策略；研究结果表明，Decipher膀胱测试可以帮助医生更好地确定哪些患者的膀胱癌侵袭性较小，可能不需要强化治疗；PORTOS签名有可能成为一种有用的临床工具，有助于为前列腺癌诊断后或正在经历生化复发的患者提供重要的放射治疗决策。

Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “potentially,” “enable,” “positioned,” “offers,” “designed,” 'ultimately,' and similar references to future periods.

。

Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024 and our subsequent Quarterly Reports on Form 10-Q.

实际结果可能与任何前瞻性声明中预测或建议的结果存在重大差异。这些陈述涉及风险和不确定性，这可能导致实际结果与我们的预测存在重大差异。可能影响这些前瞻性陈述的其他因素可以在2024年2月29日提交的10-K表年度报告和随后的10-Q表季度报告中的“风险因素”标题下找到。

Copies of these documents, when available.

这些文件的副本（如有）。

https://investor.veracyte.com

https://investor.veracyte.com

. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

。这些前瞻性声明仅在本协议签署之日起生效，除法律要求外，我们明确否认有义务更新这些前瞻性声明或实际结果可能不同的原因，无论是由于新信息、未来事件或其他原因。

Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

Veracyte、Veracyte徽标和Decipher是Veracyte，Inc.及其子公司在美国和选定国家的注册商标。

* National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

*国家综合癌症网络（National Comprehensive Cancer Network）。NCCN对其内容、使用或应用不作任何形式的保证，也不以任何方式对其应用或使用承担任何责任。